Acquired on-target alterations drive clinical resistance to p53-Y220C reactivators Abstract. The tumor suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatap...

Happy to report the first clinical evidence revealing how tumors develop resistance to p53-Y220C reactivators out today at Cancer Discovery @aacrjournals.bsky.social @mgbresearch.bsky.social @harvardmed.bsky.social @oncoalert.bsky.social @oncodaily.bsky.social #CorcoranLab #Rezatapopt #PYNNACLE

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors Mutant-selective inhibitors of KRASG12C (KRASG12Ci) have demonstrated efficacy in KRASG12C cancers. However, resistance invariably develops, resulting in short-lived responses. We aimed to define the ...

⚠️ #CorcoranLab reports "Genomic landscape of clinically acquired resistance alterations in patients treated with #KRASG12C inhibitors", a work led by our brilliant Austrian postdoc Jakob Riedl! @mgbresearch.bsky.social @fwf-at.bsky.social @harvardmed.bsky.social @oncoalert.bsky.social #crcsm #lcsm

TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer Abstract. Purpose: Antibody-drug conjugates (ADCs) harboring topoisomerase I (TOP1) inhibitor payloads have improved survival for patients with metastatic breast cancer (MBC). However, knowledge of AD...

Incidence and characterization of TOP1 mutations arising in the setting of ADC resistance in metastatic breast cancer, and the potential impact on mediating cross-resistance to sequential ADCs! @harvardmed.bsky.social @breastcancernow.bsky.social #CorcoranLab #bcsm #biomarkers #resistance